
In the second part of a two-part interview, Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center explains how patients are monitored after a complete response to dostarlimab, what longer follow-up needs to show, and how avoiding chemoradiation and surgery changes patients' lives.








